Pablo Legorreta is founder and CEO of Royalty Pharma, the leader in the acquisition of revenue-producing intellectual property with over $16 billion in royalty asset. Royalty Pharma funds innovation in life sciences, indirectly, when it acquires existing royalties from the original innovators (academic institutions, research hospitals, foundations and inventors) or, directly, when it partners with biopharmaceutical companies to co-develop and co-fund products in late-stage human clinical trials. Legorreta serves on the Boards of the New York Academy of Sciences, Rockefeller University, the Hospital for Special Surgery, and the Pasteur Foundation (U.S. affiliate of the French Institut Pasteur). Legorreta founded and is current Chairman of Alianza Médica para la Salud (AMSA), a privately-funded, not-for-profit foundation that provides scholarships to study abroad to Latin American doctors and healthcare providers. Prior to Royalty Pharma, Legorreta spent a decade at Lazard Frères in Paris and New York providing cross-border M&A and corporate finance advisory to U.S. and European corporations. Legorreta received a degree in industrial engineering from Universidad Iberoamericana (Mexico City).